Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trial
Official title:
A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01977651 -
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
|
Phase 4 | |
| Recruiting |
NCT04015622 -
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
|
Phase 2 | |
| Recruiting |
NCT06344715 -
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
|
Phase 1 | |
| Recruiting |
NCT05983198 -
A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06134232 -
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
|
Phase 3 | |
| Recruiting |
NCT06126731 -
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05806814 -
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT05658003 -
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05670106 -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
|
Phase 2 | |
| Recruiting |
NCT06334432 -
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04691804 -
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 3 | |
| Completed |
NCT03896984 -
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
|
||
| Completed |
NCT03074032 -
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT05032040 -
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
|
Phase 2 | |
| Completed |
NCT03071328 -
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
|
Early Phase 1 | |
| Active, not recruiting |
NCT02649790 -
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
|
Phase 1/Phase 2 | |
| Completed |
NCT03030885 -
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
| Terminated |
NCT03712930 -
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
|
Phase 2 | |
| Recruiting |
NCT06241846 -
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
|
Phase 2 |